Epidemiology of extended-spectrum beta-lactamase producing gram-negative bacilli at Siriraj Hospital, Thailand, 2003

Southeast Asian Journal of Tropical Medicine and Public Health

Volumn 36, Issue 6, 2005, Pages 1503-1509

  Chayakulkeeree, Methee ^a   Junsriwong, Pichai ^a   Keerasuntonpong, Anuwat ^a   Tribuddharat, Chanwit ^a   Thamlikitkul, Visanu ^a  

^a MAHIDOL UNIVERSITY   (Thailand)

Author keywords

[No Author keywords available]

Indexed keywords

EID: 33645019521     PISSN: 01251562     EISSN: 26975718     Source Type: Journal    
DOI: None     Document Type: Article

References (25)

1. Aswapokee N, Pruksachatvuthi S, Charoensook B. Prevalence and susceptibility patterns of bacteria producing extended-spectrum beta-lactamases in a university hospital. J Infect Dis Antimicrob Agents 1994; 11: 49-53.
2. Biedenbach DJ, Johnson DM, Jones RN. In vitro evaluation of cefepime and other broad-spectrum beta-lactams in eight medical centers in Thailand. The Thailand Antimicrobial Resistance Study Group. Diagn Microbiol Infect Dis 1999; 35: 325-31.
3. Chanawong A, M'Zali FH, Heritage J, Lulitanond A, Hawkey PM. SHV-12, SHV-5, SHV-2a and VEB-1 extended-spectrum beta-lactamases in Gram-negative bacteria isolated in a university hospital in Thailand. J Antimicrob Chemother 2001; 48: 839-52.
4. Cheng Y, Chen M. Extended-spectrum beta-lactamases in clinical isolates of Enterobacter gergoviae and Escherichia coli in China. Antimicrob Agents Chemother 1994; 38: 2838-42.
5. Ho PL, Chan WM, Tsang KW, Wong SS, Young K. Bacteremia caused by Escherichia coli producing extended-spectrum beta-lactamase: a case-control study of risk factors and outcomes. Scand J Infect Dis 2002; 34: 567-73.
6. Jacoby GA, Medeiros AA. More extended-spectrum beta-lactamases. Antimicrob Agents Chemother 1991; 35: 1697-704.
7. Kang CI, Kim SH, Park WB, et al. Bloodstream infections due to extended-spectrum beta-lactamase-producing Escherichia coli and Klebsiella pneumoniae: risk factors for mortality and treatment outcome, with special emphasis on antimicrobial therapy. Antimicrob Agents Chemother 2004a; 48: 4574-81.
8. Kang CI, Kim SH, Kim DM, et al. Risk factors for and clinical outcomes of bloodstream infections caused by extended-spectrum beta-lactamase-producing Klebsiella pneumoniae. Infect Control Hosp Epidemiol 2004b; 25: 860-7.
9. Kim J, Kwon Y, Pai H, Kim JW, Cho DT. Survey of Klebsiella pneumoniae strains producing extended-spectrum beta-lactamases: prevalence of SHV-12 and SHV-2a in Korea. J Clin Microbiol 1998; 36: 1446-9.
10. Knothe H, Shah P, Krcmery V, Antal M, Mitsuhashi S. Transferable resistance to cefotaxime, cefoxitin, cefamandole and cefuroxime in clinical isolates of Klebsiella pneumoniae and Serratia marcescens. Infection 1983; 11: 315-7.
11. Lautenbach E, Patel JB, Bilker WB, Edelstein PH, Fishman NO. Extended-spectrum beta-lactamase-producing Escherichia coli and Klebsiella pneumoniae: risk factors for infection and impact of resistance on outcomes. Clin Infect Dis 2001; 32: 1162-71.
12. Lin MF, Huang ML, Lai SH. Risk factors in the acquisition of extended-spectrum beta-lactamase Klebsiella pneumoniae: a case-control study in a district teaching hospital in Taiwan. J Hosp Infect 2003; 53: 39-45.
13. Martinez-Martinez L, Pascual A, Jacoby GA. Quinolone resistance from a transferable plasmid. Lancet 1998; 351: 797-9.
14. Naumovski L, Quinn JP, Miyashiro D, et al. Outbreak of ceftazidime resistance due to a novel extended-spectrum beta-lactamase in isolates from cancer patients. Antimicrob Agents Chemother 1992; 36: 1991-6.
15. National Committee for Clinical Laboratory Standards. Performance standard for antimicrobial disk susceptibility tests. Approved standard M7-A5. Wayne, Pa: National Committee for Clinical Laboratory Standards, 2000.
16. Nathisuwan S, Burgess DS, Lewis JS, 2nd. Extended-spectrum beta-lactamases: epidemiology, detection, and treatment. Pharmacotherapy 2001; 21: 920-8.
17. Paterson DL, Ko WC, Mohapatra S, et al. Klebsiella pneumoniae bacteremia: impact of extended spectrum beta-lactamase (ESBL) production in a global study of 216 patients [Abstract]. Presented at Toronto, Ontario, Canada: 37th Interscience Conference on Antimicrobial Agents and Chemotherapy; September 28 to October 1, 1997.
18. Paterson DL, Mulazimoglu L, Casellas JM, et al. Epidemiology of ciprofloxacin resistance and its relationship to extended-spectrum beta-lactamase production in Klebsiella pneumoniae isolates causing bacteremia. Clin Infect Dis 2000; 30: 473-8.
19. Paterson DL, Ko WC, Von Gottberg A, et al. Antibiotic therapy for Klebsiella pneumoniae bacteremia: implications of production of extended-spectrum beta-lactamases. Clin Infect Dis 2004a; 39: 31-7.
20. Paterson DL, Ko WC, Von Gottberg A, et al. International prospective study of Klebsiella pneumoniae bacteremia: implications of extended-spectrum beta-lactamase production in nosocomial Infections. Ann Intern Med 2004b; 140: 26-32.
21. Pena C, Pujol M, Ricart A, et al. Risk factors for faecal carriage of Klebsiella pneumoniae producing extended spectrum beta-lactamase (ESBL-KP) in the intensive care unit. J Hosp Infect 1997; 35: 9-16.
22. Pena C, Pujol M, Ardanuy C, et al. Epidemiology and successful control of a large outbreak due to Klebsiella pneumoniae producing extended-spectrum beta-lactamases. Antimicrob Agents Chemother 1998; 42: 53-8.
23. Rahal JJ, Urban C, Horn D, et al. Class restriction of cephalosporin use to control total cephalosporin resistance in nosocomial Klebsiella. JAMA 1998; 280: 1233-7.
24. Rice LB, Willey SH, Papanicolaou GA, et al. Outbreak of ceftazidime resistance caused by extended-spectrum beta-lactamases at a Massachusetts chronic-care facility. Antimicrob Agents Chemother 1990; 34: 2193-9.
25. Yagi T, Kurokawa H, Shibata N, Shibayama K, Arakawa Y. A preliminary survey of extended-spectrum beta-lactamases (ESBLs) in clinical isolates of Klebsiella pneumoniae and Escherichia coli in Japan. FEMS Microbiol Lett 2000; 184: 53-6.